In the present study, we sought to address these issues by utilizing the highly selective HDAC6 inhibitor Tubastatin A (TA) and HDAC6 knockdown in a mouse model of ischemia- and cisplatin-induced AKI. Here, HDAC6 is linked to ischemia.